Swiss pharma giant Roche had a limited presence in metabolic disease, but the firm has agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, rivaling the dominance of next-gen obesity drug developers Novo Nordisk and Eli Lilly. Carmot had been a rising star in biotech, attracting significant funding, including a $150 million…
Bausch Health to fork over $300 million in diabetes antitrust lawsuit
Bausch Health (NYSE/TSX:BHC), formerly known as Valeant Pharmaceuticals, has agreed to pay $300 million to settle allegations that the company paid rivals to keep a generic version of Glumetza off the market. In 2015, the Laval, Canada–based company increased the drug’s price by almost eight-fold. The plaintiffs, drug distributor companies, in the class-action suit filed…
Boehringer Ingelheim teams up with GoodRx on cost-savings initiative
Boehringer Ingelheim (Ingelheim, Germany) has teamed up with the prescription drug pricing tracker GoodRx (NSDQ:GDRX) to facilitate patients’ access to cost savings. For instance, people with type 2 diabetes or chronic obstructive pulmonary disease (COPD) can use GoodRx to enroll in copay programs for relevant Boehringer Ingelheim drugs. The two companies estimate that the alliance…